Protein-based path for treating cancers and other diseases

Neuroscientists pinpoint genes tied to dementia

Detecting signs of neurodegeneration earlier and more accurately

APOE gene is a promising target for therapeutic approaches to Alzheimer's

A Tel Aviv University (TAU) study suggests a new target for Alzheimer's (lat. morbus Alzheimerianus) research: the APOE gene. This gene has two faces: a healthy form called APOE3 and a disease-related pathological form called APOE4. Researchers have developed a novel mechanism and approach with which to convert the 'bad' APOE4 to the 'good' APOE3. The research was led by Prof. Daniel M. Michaelson, Director of the Eichenbaum Laboratory of Alzheimer's Disease Research and incumbent of the Myriam Lebach Chair in Molecular Neurodegeneration at TAU's Faculty of Life Sciences, together with Anat Boehm-Cagan, the Eleanore and Harold Foonberg Doctoral Fellow in Alzheimers Disease Research, and in collaboration with the commercial company Artery Ltd., based in California.

by
26 days ago

Drug dramatically reduces risk of dangerous blood clots in cancer patients

The first approach for safely preventing blood clots (or venous thromboembolism) in people with cancer (lat. Carcinoma) has been provided by the researchers at the University of Ottawa (UOTTAWA).  About half of people newly diagnosed with solid cancer could be candidates for the strategy, which involves a low dose of a direct oral anticoagulant called apixaban. This study shows for the first time that the researchers can safely prevent these clots in many people with cancer. A key part of the study was the identification of cancer patients with a higher risk of developing blood clots. This was done using the Khorana score, which is based on blood tests results and other clinical factors.

by
26 days ago

A new test points to Alzheimer's before the first symptoms

The researcher's group had created an innovative blood test for Alzheimer's disease diagnostic of at-risk patients years before first possible symptoms appear. Deposits of amyloid-beta, or plaques in the brain, are considered the most probable cause of Alzheimer's disease. A new blood test, developed by an international team of scientists, measures their concentration and allows to make a diagnostic.

by
26 days ago

A citrus skin can help to treat glaucoma

Stem cell treatment of Alzheimer's and Parkinson's diseases

Low-frequency hippocampal-cortical activity of the brain

A gene-editing technology will help to study disease-related mutations

The group of scientists has developed an innovational method to modify a single DNA base in the human genome with absolute precision. The most significant advantage of this technology is that it has the ability to control repair mechanisms of the cell, providing pairs of genetically matched cells for investigating mutations connected with various disease.

by
26 days ago

How a promising Alzheimer's drug turns back the cellular clock

A promising Alzheimer's drug that works on the molecular level has been identified by Salk Institute scientists. Alzheimer's is a devastating disease, and with the world's average population getting older, its effects will be felt further and wider in the future. A drug dubbed J147, developed by the Salk Institute, is one of the most promising candidates to treat Alzheimer's, but just how it worked at the molecular level remained a mystery. 

by
26 days ago

Tau-aggregation inhibitor therapy for Alzheimer's disease

A new treatment for Alzheimer's disease is being developed by the biopharmaceutical company TauRx Pharmaceuticals, Ltd. Most studies aimed at preventing or purifying the pathology of β-amyloids conducted by scientists have not shown efficacy in recent years. Consequently, scientists continue research with drugs aimed at the same goals and mechanisms.

by
26 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM